A Novel, Highly Selective IRAK1 Inhibitor Jh-X-119-01 Shows Synergistic Tumor Cell Killing with Ibrutinib in MYD88 Mutated B-Cell Lymphoma Cells
Authors: Yang Guang , Hatcher John , Wang Jinhua , Liu Xia , Munshi Manit , Chen Jiaji , Xu Lian , Tsakmaklis Nickolas , Demos Maria , Kofides Amanda , Chan Gloria , Hunter Zachary , Patterson Christopher , Gustine Joshua , Castillo Jorge J. , Gray Nathanael , Treon Steven P , Buhrlage Sara 
Published: April 2021

Abstract

Activating mutations in MYD88 are present in many B-cell lymphoproliferative disorders including WM (95%), ABC DLBCL (39%), Primary CNS Lymphoma (80-90%), Marginal Zone Lymphoma (6-10%) and Chronic Lymphocytic Leukemia (4-8%). In MYD88 mutated WM and ABC DLBCL cells, MYD88 triggers NF-kB pro-growth and survival signaling through divergent pathways driven by BTK and IRAK4/IRAK1 (Ngo et al, Nature 2011; Yang et al, Blood 2013). Ibrutinib targets BTK, and has shown high levels of activity in MYD88 mutated WM, ABC DLBCL and PCNSL. Responses however are partial, and complete remissions are lacking. We therefore sought to clarify if persistent IRAK4/IRAK1 signaling was responsible for survival of malignant lymphoplasmacytic cells (LPC) in WM patients on ibrutinib. We observed by flow cytometric analysis that while BTK activation was suppressed in WM patients on ibrutinib for &gt;6 months, both IRAK4 and IRAK 1 remained hyperactivated. Treatment of LPC from patients on ibrutinib with a toolbox IRAK4/IRAK1 inhibitor resulted in marked reduction of NF-kB and induction of apoptosis. Subsequently, we performed lentiviral transduction studies in MYD88 mutated BCWM.1 cells, and observed in an inducible model system that knockdown of IRAK1 produced more robust apoptotic effects versus IRAK4 (Figure 1A). Given these findings, we have pursued a medical chemistry campaign to develop a potent and highly selective inhibitor of IRAK1 kinase activity, JH-X-119-01. JH-X-119-01 inhibited IRAK1 biochemically with an IC50 of 9.3 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 µM, and showed exceptional Kinome selectivity with off-target inhibition of only two kinases, YSK4 and MEK3 (Figure 1B). Mass spec labelling studies were used to confirm that JH-X-119-01 irreversibly labelled IRAK1 at cysteine 302. JH-X-119-01 showed antiproliferative effects on MYD88 mutated WM and ABC DLBCL cells. Importantly, the combination of JH-X-119-01 with Ibrutinib led to synergistic tumor cell killing in MYD88 mutated WM and ABC-DLBCL cells, and suppression of NF-ĸB activation (Figure 1C). In vivo PK studies revealed a favorable profile for JH-X-119-01 with a moderate half-life of 1.61 hours, a Cmax of 9.95 µM, and a low clearance of 18.84 mL/min/kg when dosed IV. Our findings evidence the development of a novel, highly selective IRAK1 kinase inhibitor, JH-X-119-01, that shows specific inhibition of IRAK1 kinase activity and a reduction of tumor cell survival in MYD88 mutated WM. Importantly, JH-X-119-01 shows synergistic tumor cell killing with ibrutinib in MYD88 mutated WM and ABC-DLBCL cells. This study provides a framework for the development of highly selective IRAK1 inhibitors for use alone, and in combination with ibrutinib in MYD88 mutated B-cell lymphomas.
Figure 1 Figure 1.

Disclosures
Castillo: Janssen: Consultancy, Research Funding; Abbvie: Research Funding; Millennium: Research Funding; Pharmacyclics: Consultancy, Research Funding. Treon: Pharmacyclics: Consultancy, Research Funding.